298 related articles for article (PubMed ID: 22876543)
21. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
Alharbi M; Pinto G; Finidori G; Souberbielle JC; Guillou F; Gaubicher S; Le Merrer M; Polak M
Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235
[TBL] [Abstract][Full Text] [Related]
22. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.
Forin V; Arabi A; Guigonis V; Filipe G; Bensman A; Roux C
Joint Bone Spine; 2005 Jul; 72(4):313-8. PubMed ID: 16038843
[TBL] [Abstract][Full Text] [Related]
23. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
Lee YS; Low SL; Lim LA; Loke KY
Eur J Pediatr; 2001 Nov; 160(11):641-4. PubMed ID: 11760017
[TBL] [Abstract][Full Text] [Related]
24. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
25. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
[TBL] [Abstract][Full Text] [Related]
26. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J; Lin X; Sun L; Zhang Q; Jiang Y; Wang O; Xing X; Xia W; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1827-1836. PubMed ID: 38198649
[TBL] [Abstract][Full Text] [Related]
28. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Rauch F; Munns C; Land C; Glorieux FH
J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
[TBL] [Abstract][Full Text] [Related]
29. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.
Rauch F; Cornibert S; Cheung M; Glorieux FH
Bone; 2007 Apr; 40(4):821-7. PubMed ID: 17223617
[TBL] [Abstract][Full Text] [Related]
30. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Nasomyont N; Hornung LN; Gordon CM; Wasserman H
Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
[TBL] [Abstract][Full Text] [Related]
31. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
32. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
33. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
34. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
[TBL] [Abstract][Full Text] [Related]
35. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
36. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
Bajpai A; Kabra M; Gupta N; Sharda S; Ghosh M
J Pediatr Orthop; 2007 Mar; 27(2):225-7. PubMed ID: 17314651
[TBL] [Abstract][Full Text] [Related]
37. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
38. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
39. Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
Kashii M; Kanayama S; Kitaoka T; Makino T; Kaito T; Iwasaki M; Kubota T; Yamamoto T; Ozono K; Yoshikawa H
J Bone Miner Metab; 2019 May; 37(3):545-553. PubMed ID: 30187275
[TBL] [Abstract][Full Text] [Related]
40. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]